Sub therapeutic drug levels among HIV/TB co-infected patients receiving Rifampicin in northwestern Tanzania: A cross sectional clinic based study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sub therapeutic drug levels among HIV/TB co-infected patients receiving Rifampicin in northwestern Tanzania: A cross sectional clinic based study

Published:2017-08-01 Issue:3 Volume:53 Page:271-279
ISSN:2090-5068
Container-title:Alexandria Journal of Medicine
language:en
Short-container-title:Alexandria Journal of Medicine

Author:

Gunda Daniel W.¹,Kalluvya Samuel E.¹,Kasang Christa²³,Kidenya Benson R.⁴,Mpondo Bonaventura C.⁵,Klinker Hartwig⁶

Affiliation:

1. Department of Internal Medicine, Weill Bugando School of Medicine, 1464 Mwanza, Tanzania

2. Institutes of Virology and Immunobiology, University of Würzburg, Würzburg, Germany

3. Medical Mission Institute, Würzburg, Germany

4. Department of Biochemistry and Molecular Biology, Weill Bugando School of Medicine, 1464 Mwanza, Tanzania

5. Department of Internal Medicine, University of Dodoma, 1935 Dodoma, Tanzania

6. Division of Infectious Diseases, Department of Internal Medicine, University of Würzburg, Würzburg, Germany

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1016/j.ajme.2016.10.001

Reference55 articles.

1. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin

2. The Growing Burden of Tuberculosis

3. When to Start Antiretroviral Therapy in HIV-Associated Tuberculosis

4. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections

5. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends and Progress on Antibiotic-Resistant Mycobacterium tuberculosis and Genes in relation to Human Immunodeficiency Virus;Canadian Journal of Infectious Diseases and Medical Microbiology;2023-11-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3